

 Early Warning System

EIB-20200875
REGENLAB (EGF VD)



Quick Facts

| | |
|--------------------------------|--|
| Countries | France, Italy |
| Financial Institutions | European Investment Bank (EIB) |
| Status | Approved |
| Bank Risk Rating | U |
| Voting Date | 2021-09-30 |
| Borrower | REGEN LAB FRANCE SAS |
| Sectors | Education and Health, Industry and Trade |
| Investment Type(s) | Loan |
| Investment Amount (USD) | \$ 15.54 million |
| Project Cost (USD) | \$ 61.06 million |



Project Description

According to the bank website, the project concerns developing, manufacturing and selling medical devices used for autologous cell therapies, particular in Platelet Rich Plasma (PRP) and autologous tissue engineering with Hyaluronic Acid (HA) in the field of orthopaedics and regenerative medicine. Recently, the company has developed a new model of its devices for the preparation of convalescent plasma (CP) - antibody-rich products that are collected from eligible donors who have recovered from COVID-19. The proposed transaction will support research, development and innovation (RDI) activities required to complete the development of the Promoter's products in the pipeline. Moreover, the project will also encompass the financing of capital investments required to scale-up the manufacturing process and increase the industrial capacity of the Promoter.



Investment Description

- European Investment Bank (EIB)



| Private Actor 1 | Private Actor 1 Role | Private Actor 1 Sector | Relation | Private Actor 2 | Private Actor 2 Role | Private Actor 2 Sector |
|-----------------|----------------------|------------------------|----------|----------------------|----------------------|------------------------|
| - | - | - | - | REGEN LAB FRANCE SAS | Client | Education and Health |



Contact Information

ACCESS TO INFORMATION

You can submit an information request for project information at: <https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm>

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: <http://www.eib.org/complaints/form> via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check:

http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at:

<http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces>